Janssen Seeks to Expand Darzalex Use for Multiple Myeloma Patients
Janssen Biotech has submitted a supplemental Biologics License…
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreWhile myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreJanssen Biotech has submitted a supplemental Biologics License…
Patients with heavily treated multiple myeloma have promising response…
With advances in treatment for multiple myeloma, some studies…
Adding Darzalex (daratumumab) to the treatment of multiple myeloma…
Empliciti (elotuzumab), a monoclonal antibody, is approved in both the…
Juno Therapeutics and privately held biotech…